Sartorius AG

1SRT3

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    14,242

Stocks News & Analysis

stocks

Undervalued tech share oversold on AI fears

Has the market overlooked this ASX tech share?
stocks

Margins have bottomed for ASX listed consumer goods company

Impact of tariffs have been priced in.
stocks

SpaceX rally continues, expanding sky-high valuations

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,053.7031.900.35%
CAC 408,421.1446.84-0.55%
DAX 4024,985.8240.98-0.16%
Dow JONES (US)51,564.7072.150.14%
FTSE 10010,363.2736.43-0.35%
HKSE23,602.99321.82-1.35%
NASDAQ26,517.93496.281.91%
Nikkei 22572,648.471,398.411.96%
NZX 50 Index13,491.883.75-0.03%
S&P 5007,500.5880.481.08%
S&P/ASX 2008,835.8033.900.39%
SSE Composite Index4,074.9615.52-0.38%

Market Movers